...
首页> 外文期刊>Journal of nanomaterials >Fabrication of a Thermosensitive In Situ Gel Nanoemulsion for Nose to Brain Delivery of Temozolomide
【24h】

Fabrication of a Thermosensitive In Situ Gel Nanoemulsion for Nose to Brain Delivery of Temozolomide

机译:制造灭火器的原位凝胶纳米乳液中滴血瘤的滴鼻液

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In this study, a thermosensitive in situ gel nanoemulsion was formulated by a low energy method for intranasal delivery of temozolomide to bypass the blood-brain barrier and optimize chemotherapy for glioblastoma. Various amounts of Labrasol, Transcutol?P, and Triacetin were chosen as nanoemulsion components based on the solubility and the partial pseudoternary phase diagrams studies. Poloxamer derivatives added to the selected nanoemulsion and gelling temperature optimized. The prepared in situ gel nanoemulsion containing temozolomide showed a mean droplet size of , a polydispersity index value of , and desirable pH and viscosity. In vitro release studies revealed that both nanoemulsion and in situ gel preparation have sustained release pattern in comparison to the control solution. Visual evaluation and droplet size and polydispersity index measurements showed both nanoemulsion and in situ gel nanoemulsion were stable during heating-cooling and freeze-thaw cycles and also centrifugation. Mucoadhesion percentage of in situ gel nanoemulsion was regarding ex vivo studies, which had a significant rise in comparison to control solution and nanoemulsion. Permeation across the nasal mucosa was 1.43- and 1.52-fold higher than the control solution for nanoemulsion and in situ nanoemulsion, respectively. Gamma scintigraphy study showed brain accumulation of developed nanoemulsion formulations. Our studies demonstrated optimized formulation has suitable physicochemical properties, desirable release profile, enhanced permeation across the nasal mucosa, and prolonged resistance time at the nasal mucosa. Therefore, in situ gel nanoemulsion would be an effective novel nasal delivery system for the treatment of glioblastoma.
机译:在这项研究中,热敏原位凝胶纳米乳液是通过在替莫唑胺的鼻内递送的低能量方法配制,以绕过血 - 脑屏障和优化化疗成胶质细胞瘤。的Labrasol,TRANSCUTOL?P,和甘油三乙酸酯的各种量被选为基于溶解性和局部伪三元相图的研究纳米乳剂组分。泊洛沙姆衍生物加入到优化所选择的纳米乳剂和凝胶化温度。在含有替莫唑胺原位凝胶纳米乳剂所制备的显示出的平均液滴尺寸,多分散性指数值,和所需的pH和粘度。体外释放的研究显示,这两种纳米乳剂和原位凝胶制备具有持续释放模式相比于对照溶液。视觉评估和液滴尺寸和多分散指数的测量表明二者的纳米乳剂和原位凝胶纳米乳液加热 - 冷却和冻融循环,并且还在离心期间是稳定的。原位凝胶纳米乳液黏膜粘附百分比有关体外研究,其中有相比于对照液和纳米乳剂显著上升。通过鼻粘膜渗透是1.43-和分别1.52倍对纳米乳剂和原位纳米乳剂对照溶液更高。 γ扫描研究表明,纳米乳发达配方的大脑积累。我们的研究证实了优化制剂具有合适的物理化学性质,理想的释放曲线,通过鼻粘膜增强渗透,并在鼻粘膜电阻延长时间。因此,在原位凝胶纳米乳液将是成胶质细胞瘤的治疗有效的新型经鼻递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号